<DOC>
	<DOCNO>NCT01959516</DOCNO>
	<brief_summary>This study purpose study profile glycopyrronium ( NVA237 ) tiotropium first hour dose impact pulmonary function , COPD symptoms ability perform daily activity patient .</brief_summary>
	<brief_title>Effect Glycopyrronium Morning Symptoms Pulmonary Function Patients With Moderate Severe COPD</brief_title>
	<detailed_description>Randomized , multicenter , blind , two-period cross-over design . Each treatment last 28 day . All patient receive treatment cross-over design , wash-out period 14-19 day . The total duration study patient approximately 70 day ( randomization ) plus 30 day safety follow-up .</detailed_description>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Male female adult age ≥ 40 year . Cooperative outpatient clinical diagnosis moderate severe COPD confirm spirometry accord GOLD criterion 2013 include follow : ) Current exsmokers smoke history least 10 pack year ( e.g.10 pack year = 1 pack /day x 10 year ½ pack/day x 20 year ) . An exsmoker may define subject smoke ≥ 6 month Screening . b ) Patients airflow limitation indicate postbronchodilator FEV1 &lt; 80 % ≥ 40 % predict normal value Visit 2 ( Post bronchodilator refers within 1015 min inhalation 400 µg ( 4x100 µg ) salbutamol ) . c ) .Postbronchodilator FEV1/FVC &lt; 0.7 Visit 2 ( Post bronchodilator refers within 1015 min inhalation 400 µg ( 4x100 µg ) salbutamol ) . Patients COPD Assessment Test ( CAT ) score ≥ 10 Visit 2 . Exclusion criterion : Patients COPD exacerbation require systemic glucocorticosteroid treatment antibiotic and/or hospitalization 6 week prior Visit 1 . In event exacerbation occur Screening period ( Visits 12 ) , patient must discontinue study . The patient may reenrolled inclusion/exclusion criterion meet . Only one reenrollment allow . Patients respiratory tract infection within 6 week prior Visit 1 . Patients develop respiratory tract infection Visit 1 Visit 2 must discontinue trial , may permit reenrol later date inclusion/exclusion criterion meet . Only one reenrollment allow . Patients longacting bronchodilator therapy . Those patient may enter study bronchodilator withdrawal 10day washout period ( rescue salbutamol allow bronchodilator therapy washout ) . Patients fixed combination long act β2agonists/inhaled corticosteroid ( LABA/ICS ) therapy screen must switch equivalent dose ICS monotherapy salbutamol rescue . Patients receive prohibit COPDrelated medication specify Table 51 must undergo require washout period prior Visit 2 . Patients clinical history asthma . Patients concomitant pulmonary disease , e.g . pulmonary tuberculosis clinically significant bronchiectasis . Patients alpha1antitrypsin deficiency . Patients contraindication LAMA treatment include medical history symptomatic prostatic hypertrophy , bladder neck obstruction , narrowangle glaucoma severe renal impairment ( estimate glomerular filtration rate 30 ml/min/1.73 m2 ) document previous 6 month . Patients history unstable cardiovascular disease arrhythmia include atrial fibrillation/flutter long QT syndrome whose rest QTcF ( calculate accord Fridericia QT correction formula prefer , Bazett acceptable ) prolong ( ≥ 450 msec male ≥ 460 msec female ) screening ( Visit 1 ) baseline ( Visit 2 , baseline 1 ) . Concomitant use agent know prolong QT interval unless permanently discontinue duration study . Patients contraindicate treatment , history reactions/ hypersensitivity follow inhaled drug , drug similar class component thereof : anticholinergic agent long short act 2 agonist sympathomimetic amine excipients trial medication ( lactose monohydrate and/or magnesium estearate ) Patients whose body mass index ( BMI ) less 15 great 40 kg/m2 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . Other exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>COPD , early morning symptom</keyword>
</DOC>